Articles
Study Results

Retatrutide Weight Loss Timeline: Week-by-Week Results from Trials

How fast retatrutide worked in the trials: about 3% by week 4, 9–10% by week 12 and 28.3% at 80 weeks on 12 mg

Written By
retaweightloss.com
Updated on
11 Nov 2026
Time to read
5 min read
Category
Study Results
Retatrutide weight loss timeline: how fast weight fell week by week in the trials

Retatrutide Weight Loss Timeline: Week-by-Week Results from Trials

How fast retatrutide worked in the trials: about 3% by week 4, 9–10% by week 12 and 28.3% at 80 weeks on 12 mg

By
RetaWeightLoss.com
Created on:
24 Feb 2026
Updated on:
11 Nov 2026
Share this post

How Fast Does Retatrutide Work? The Short Answer

In the trials, retatrutide began lowering weight in the first week. On the 12 mg dose, people had lost about 1% of their body weight after week 1 (Phase 2), about 3% by week 4 and about 9–10% by week 12, based on the published trial graphs.

For a person starting at 248 lb, the average starting weight in TRIUMPH-1, that is about 7 lb after one month and 22–25 lb after three months, by our calculation. The first exact figures are 17.5% at 24 weeks and 24.2% at 48 weeks in the Phase 2 trial, and 28.3% at 80 weeks in TRIUMPH-1, for people who stayed on treatment.

Week Phase 2, 12 mg TRIUMPH-1, 12 mg TRIUMPH-1, placebo At a 248 lb start (TRIUMPH-1, 12 mg)
Week 1 about 1% — — —
Week 4 (1 month) about 3% about 3% about 1% about 7 lb (3.4 kg)
Week 8 (2 months) about 6% about 6% about 1% about 15 lb (6.8 kg)
Week 12 (3 months) about 10% about 9% about 2% about 22 lb (10.1 kg)
Week 16 (4 months) about 13% about 12% about 2% about 30 lb (13.5 kg)
Week 20 (5 months) about 15% about 15% about 3% about 37 lb (16.9 kg)
Week 24 (6 months) 17.5% (reported) about 18% about 3% about 45 lb (20.3 kg)


Neither paper prints a number for these early weeks; the percentages above are read from each paper's weight graph (Figure 1A) and rounded, so treat them as approximate. The last column is our calculation from the rounded TRIUMPH-1 values for a person at the trial's average starting weight of 112.7 kg (about 248 lb); it is not a figure the trial reports. The two graphs are built differently: the Phase 2 graph shows estimates from a statistical model, while the TRIUMPH-1 graph shows the average among participants still on treatment at each visit. Even so, the two trials, published three years apart in different groups of people, show almost the same curve for the first 24 weeks. The trials were not compared head to head.

WeekAverage weight loss, 12 mgTrial
24 weeks 17.5% Phase 2 (338 adults with obesity or overweight, without diabetes)
48 weeks 24.2% Phase 2 (338 adults with obesity or overweight, without diabetes)
68 weeks 28.7% TRIUMPH-4 (445 adults with knee osteoarthritis)
80 weeks 28.3% TRIUMPH-1 (2,339 adults)
104 weeks 30.3% TRIUMPH-1 extension: selected participants originally on 12 mg (BMI 35 or more, completed 80 weeks)


From week 24 on, these are the figures the investigators report for people who stayed on treatment as intended. The rows come from different trials and populations, so they are not one continuous curve. Counting everyone who started, including people who stopped, the 80-week figure in TRIUMPH-1 was 25.0%; why the two numbers differ is explained in why retatrutide weight loss numbers differ. Retatrutide is investigational and not approved; for where it stands, see retatrutide's approval status.

Retatrutide Weight Loss Per Week in the Trials

The trials report totals at set points, not weekly amounts, but the averages give a rough pace for people on 12 mg:

  • Weeks 1–12: about 0.8% of body weight per week
  • Weeks 12–24: about 0.6–0.7% per week
  • Weeks 24–48: about 0.3% per week (Phase 2)

The average participant in TRIUMPH-1 started at 112.7 kg (about 248 lb). For that weight, 0.8% a week is roughly 2 lb (0.9 kg) a week in the first three months, and 0.3% is under 1 lb (0.3 kg) a week in the second half of the first year.

These are our calculations from group averages, not figures the trials report. Weight does not come off at an even rate, individual results varied widely, and the pace slowed over time.

Weeks 1–4: How Soon Weight Loss Started

Treatment in the trials started at a lower dose that was increased step by step, so in the first weeks participants were not yet on the dose they had been assigned. Weight still began to fall right away. The Phase 2 trial weighed participants after the first week, and the graph shows a small drop of about 1–2% in every retatrutide group, about 1% on 12 mg.

Neither paper's weight graph (Figure 1A) has a point for weeks 2 or 3: the Phase 2 graph goes from week 1 straight to week 4, and the TRIUMPH-1 graph's first point after the start is week 4. Between those two points, the 12 mg average went from about 1% to about 3%.

By week 4, people assigned to 12 mg had lost about 3% of their weight in both trials (Phase 2 and TRIUMPH-1), compared with about 1% on placebo in TRIUMPH-1. For the average TRIUMPH-1 participant, 3% is about 7 lb (3.4 kg). At this stage, the TRIUMPH-1 curves for all three doses lie almost on top of each other; in Phase 2, the groups clustered by starting dose, with those who started higher losing a little more early on.

This is also when side effects were most common; see When Retatrutide Side Effects Were Most Common below.

Was the First Month on Retatrutide Slower? What the Graphs Show

Not by much. On 12 mg, the graphs show roughly the same amount of loss in each of the first three months: about 3% by week 4, about 6% by week 8 and about 9–10% by week 12. In other words, the first four weeks produced about a third of the three-month total, even though participants had not yet reached their assigned dose. After that, the pace stayed about the same until around week 20 in TRIUMPH-1 and eased a little after week 16 in Phase 2. In neither trial was the first month slower than the two months that followed.

These are group averages read from the published graphs, and averages do not show how much individual participants differed from one another in the first weeks.

Weeks 5–12: Results at 2 and 3 Months

People on 12 mg had lost about 6% by week 8 and about 9–10% by week 12: roughly 10% on the Phase 2 graph and 9% on the TRIUMPH-1 graph. For the average TRIUMPH-1 participant, 9–10% at three months is about 22–25 lb (10–11 kg) by our calculation. The TRIUMPH-1 placebo group had lost about 2%.

The doses start to separate here. In TRIUMPH-1, the 4 mg group fell behind after week 8, reaching about 8.6% at week 12 compared with about 9.2% on 12 mg, while the 9 mg and 12 mg groups stayed close together until about week 16.

Weeks 13–24: Results at 4 to 6 Months

Loss continued at about the same pace in TRIUMPH-1 until around week 20 and a little more slowly in Phase 2 after week 16. On 12 mg, the graphs show about 12–13% at week 16 and about 15% at week 20 in both trials. At week 24, the Phase 2 trial reported an average of 17.5% on 12 mg, compared with 1.6% on placebo; the TRIUMPH-1 graph shows about 18% at the same point, about 45 lb (20 kg) for the average participant. Phase 2 reported 24-week results for the other doses too: 7.2% on 1 mg, 11.8–13.9% on 4 mg and 16.7–17.9% on 8 mg, depending on the starting dose.

Weeks 25–48: Retatrutide Results at 6 to 11 Months

By week 48, people on 12 mg in Phase 2 had lost an average of 24.2%, compared with 2.1% on placebo. The investigators wrote that weight was still falling when treatment ended and that a plateau had not yet been reached.

In the Phase 2 paper's analysis of weight-loss targets (Figure 1B), at 48 weeks on 12 mg, 100% of participants had lost at least 5% of their weight, 93% at least 10%, 83% at least 15%, 63% at least 20%, 48% at least 25% and 26% at least 30%.

Weeks 49–68: TRIUMPH-4 Phase 3 Results

TRIUMPH-4, which Lilly described in December 2025 as its first successful Phase 3 trial of retatrutide, followed 445 adults with obesity or overweight and knee osteoarthritis for 68 weeks. Lilly reported average weight loss of 28.7% with 12 mg and 26.4% with 9 mg, compared with 2.1% on placebo, for people who stayed on treatment. These results are company-reported; we found no published paper as of November 2026.

Weeks 69–80: TRIUMPH-1

TRIUMPH-1 enrolled 2,339 adults with obesity or overweight and without diabetes and followed them for 80 weeks; it was published in the New England Journal of Medicine in September 2026. With 12 mg, weight fell by an average of 28.3%, compared with 2.2% on placebo, for people who stayed on treatment. The full results by dose are in our TRIUMPH-1 results article.

According to the paper's supplementary appendix (Figure S7), 62.5% of people on 12 mg who stayed on treatment lost at least 25% of their body weight, 45.3% at least 30% and 27.2% at least 35%.

Beyond 80 Weeks: Results at Two Years

The TRIUMPH-1 paper also reports a 24-week extension. It included 532 participants, the first eligible people who had a BMI of 35 or more at the start and had completed 80 weeks without stopping treatment or lowering their dose. In the extension, all of them received 9 mg or 12 mg, whichever was the highest dose they tolerated. Those originally assigned to 12 mg had lost an average of 30.3% of their weight at week 104 for those who stayed on treatment, or 29.9% counting everyone in the extension.

Does Weight Loss Plateau on Retatrutide?

Neither published paper reports a plateau so far. In Phase 2, weight was still falling when treatment ended at 48 weeks. In the TRIUMPH-1 extension, people originally on 12 mg reached 30.3% at 104 weeks; that group was a selected subset of the trial, so the figure is not directly comparable with the 80-week average. The weekly pace did slow steadily after the first six months. Neither published paper reports data beyond week 104, so when weight loss levels off is not yet known. What happened after stopping in other trials is covered in weight regain after stopping retatrutide.

When Retatrutide Side Effects Were Most Common

In TRIUMPH-1, the most common side effects were gastrointestinal. The paper describes them as mostly transient and mild or moderate, occurring most often while the dose was being increased. The Phase 2 paper reported the same pattern, with these side effects partially mitigated in the trial groups that started on a lower dose.

Over the full 80 weeks on 12 mg in TRIUMPH-1, 42.4% of participants reported nausea at some point, compared with 14.8% on placebo, along with diarrhea (32.0% vs 13.5%) and vomiting (25.3% vs 4.8%). Side effects led 11.2% of people on 12 mg to stop treatment, compared with 4.6% on placebo (Table 3). For how long they lasted and less common effects, see the retatrutide side effects guide.

Why Retatrutide Results Vary

The averages above hide large differences between people. The published data show three that matter:

FactorWhat the trials showed
Dose At 80 weeks: 17.6% on 4 mg, 23.7% on 9 mg, 25.0% on 12 mg (TRIUMPH-1)
Sex On 12 mg at 80 weeks: women 26.3%, men 22.3% (TRIUMPH-1)
Type 2 diabetes On 12 mg at 80 weeks: 20.8% in people with type 2 diabetes who stayed on treatment (TRIUMPH-2), compared with 28.3% on the same basis in TRIUMPH-1


The first two rows count everyone randomized in TRIUMPH-1; the TRIUMPH-2 figure is company-reported by Lilly, for people who stayed on treatment, and the two trials were not compared head to head. The difference between women and men is covered in retatrutide weight loss in women vs men, and the diabetes trials in retatrutide for type 2 diabetes.

Sources

  • Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. Published June 26, 2023. DOI: 10.1056/NEJMoa2301972. (Phase 2; Table 2 and Figure 1)
  • Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. Published September 29, 2026; updated October 22, 2026. DOI: 10.1056/NEJMoa2604169. (TRIUMPH-1, Figure 1 and supplementary appendix)
  • Eli Lilly. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. December 11, 2025. (TRIUMPH-4)
  • Eli Lilly. Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes. September 29, 2026. (TRIUMPH-2)
  • Eli Lilly. What to know about retatrutide.

Medical disclaimer: This article summarizes published clinical trial results for general information only and is not medical advice. Retatrutide is an investigational drug that is not approved for any use. It is not on the market, and Lilly says no one can legally sell it for human use. Individual results in the trials varied. Nothing here is a recommendation to use, seek out or avoid any medication.

Frequently asked questions

How fast does retatrutide work for weight loss?

In the published trials, weight began to fall in the first week, even though treatment started at a lower dose that was increased step by step. On 12 mg, the Phase 2 trial shows a drop of about 1% after week 1, and both trials show about 3% by week 4 and about 9 to 10% by week 12, read from the published graphs. Weight kept falling after that, to 28.3% at 80 weeks in TRIUMPH-1 for people who stayed on treatment.

How much weight did people lose on retatrutide in the first month?

In both published trials, people assigned to 12 mg had lost about 3% of their body weight by week 4, compared with about 1% on placebo in TRIUMPH-1. These values are read from the papers' weight graphs, since no exact figure is printed for week 4. For the average TRIUMPH-1 participant, who started at about 248 lb, 3% is about 7 lb.

How much weight did people lose on retatrutide in 3 months?

By week 12, people on 12 mg had lost about 9 to 10% of their body weight: about 10% on the Phase 2 graph and about 9% on the TRIUMPH-1 graph, compared with about 2% on placebo in TRIUMPH-1. For the average TRIUMPH-1 participant, who started at about 248 lb, that is roughly 22 to 25 lb by our calculation. The first exact figure, 17.5%, was reported at 24 weeks in the Phase 2 trial.

What was the average weight loss per week in the retatrutide trials?

The trials report totals, not weekly amounts. Dividing the averages for 12 mg by time gives about 0.8% of body weight per week in the first 12 weeks, about 0.6 to 0.7% per week from week 12 to 24, and about 0.3% per week from week 24 to 48. These are rough calculations, and the pace varied between people.

Newsletter

Stay Updated on New Articles & Research

Get notified when we publish new articles, research, and insights on obesity and weight loss.
You're subscribed!
You'll get new coverage as it's published.
Oops! Something went wrong while submitting the form.